A study that followed ovarian cancer patients prior to primary treatment to 1 year post-treatment, found that patients showed significant reductions in nocturnal salivary cortisol secretion and plasma IL-6 and a more normalized diurnal cortisol rhythm at 6 months with changes maintained at 1 year (160). This evidence concerns the gene IL6 and ovarian cancer.